logo
  

Gilead Sciences Q2 Profit Down; Lifts FY Adj. Profit, Total Product Sales Outlook

Gilead Sciences Inc. (GILD) reported that its second quarter net income attributable to the company declined to $1.14 billion or $0.91 per share from $1.52 billion or $1.21 per share last year. The decrease was primarily due to higher acquired in-process research & development expenses from an upfront payment of $300 million, or $0.18 on a post-tax per share basis, related to the Dragonfly Therapeutics Inc. collaboration and higher net unrealized losses from strategic equity investments.

Quarterly non-GAAP earnings per share decreased 13% to $1.58 from $1.81 last year, primarily reflecting the Dragonfly upfront payment and Biktarvy-related royalty expense that began in the first quarter of 2022, offset partially by higher revenues. Analysts polled by Thomson Reuters expected the company to report earnings of $1.53 per share for the second quarter. Analysts' estimates typically exclude special items.

Total revenue for the second quarter 2022 increased 1% to $6.3 billion from the prior year, primarily due to increased sales in HIV and oncology products, offset partially by decreased sales of Veklury (remdesivir) and hepatitis C virus or "HCV" products. Analysts expected revenue of $5.85 billion for the second quarter.

HCV product sales decreased 18% to $448 million in the second quarter of 2022 compared to the same period in 2021, primarily driven by channel mix leading to lower average realized price and fewer patient starts.

For the full-year, the company now expects earnings per share to be in the range of $2.90 - $3.30, compared to the prior outlook of $3.00 - $3.50.

The company now expects annual non-GAAP earnings per share to be between $6.35 and $6.75, compared to the prior estimation of $6.20 and $6.70. Analysts expect annual earnings of $6.57 per share.

The company now anticipates annual total product sales to be between $24.5 billion and $25.0 billion, compared to the previous outlook of $23.8 billion - $24.3 billion. Analysts expect revenue of $24.57 billion for the year.

Annual total product sales, excluding Veklury, is expected to be between $22.0 billion to $22.5 billion, compared to the prior outlook of $21.8 billion and $22.3 billion.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Centers for Disease Control and Prevention or CDC has ended recommendations for social distancing and quarantine with a view to minimize covid-19's impact on persons, communities, and health care systems. The agency also ended recommendation for test-to-stay in schools, CNN noted. Healthcare major Johnson & Johnson, which is in the middle of a talcum powder fiasco, said it is discontinuing talc-based JOHNSON'S Baby Powder globally in 2023. The company plans to transition to an all cornstarch-based baby powder portfolio. According to the company, the commercial decision to use cornstarch in all its baby powder products was made after conducting an assessment of its portfolio Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV.
Follow RTT